Merck earnings slide to US$1.59b

Source: Agencies | July 22, 2009, Wednesday |

Print Edition

MERCK & Co said second-quarter earnings fell, hurt by the strong US dollar and lower sales of its cholesterol drugs, but favorable tax settlements helped the drug maker soundly beat profit forecasts.

Merck, which plans to acquire Schering-Plough Corp in coming months, said yesterday it earned US$1.59 billion, or 74 US cents per share. That compares with US$1.77 billion, or 82 US cents per share, in the year-earlier period.

Excluding special items, it earned 83 US cents per share. Analysts on average expected 77 US cents, according to Reuters Estimates.

Revenue fell 3 percent to US$5.90 billion but was US$70 million above the Reuters Estimate forecast. Sales would have risen 3 percent if not for the strong US dollar.

Results were helped by a 10 percent decline in marketing and administrative expenses.

The Schering-Plough acquisition is expected to close in the fourth quarter.

Manufacturing

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Merck earnings slide to US$1.59b

Email this to your friend